


IN THE CLAIMS

Replace claims 1, 5-9 and 12-14 with substitute claims 1, 5-9 and 12-

14 as follows:*

1. (Twice Amended) A combination of a carrier and a complex comprising a nucleic acid molecule and a charged copolymer of the general formula I




wherein R is an amphiphilic polymer or a homo- or hetero-bifunctional derivative thereof,

and wherein X

- i) is an amino acid or an amino acid derivative, a peptide or a peptide derivative or a spermine or a spermidine derivative; or

- ii) wherein X is



* Applicants enclose a "Version Showing Changes Made" including the amendments to the specification and to the claims.


wherein

a is H or, optionally halogen- or dialkylamino-substituted, C₁-C₆ alkyl; and

wherein

b, c and d are the same or different, optionally halogen- or dialkylamino-substituted, C₁-C₆ alkylene; or

iii) wherein X is



wherein

a is H or, optionally halogen or dialkylamino substituted, C₁-C₆ alkyl,

and wherein

b and c are the same or different, optionally halogen- or dialkylamino-substituted, C₁-C₆ alkylene; or

iv) wherein X

is a substituted aromatic compound with three functional groupings W₁Y₁Z₁,

wherein W, Y and Z have the meanings mentioned below;

wherein

W, Y or Z are the same or different groups CO, NH, O or S or a linker grouping capable of reacting with SH, OH, NH or NH₂;

and wherein the effector molecule E

is a cationic or anionic peptide or peptide derivative or a spermine or spermidine derivative or a glycosaminoglycane or a non-peptidic oligo/polycation or -anion; wherein

m and n are independently of each other 0, 1 or 2; wherein

p preferably is 3 to 20; and wherein

l is 1 to 5.

5. (Twice Amended) The combination according to claim 1, wherein a ligand for a higher eukaryotic cell is coupled to the copolymer.

6. (Twice Amended) The combination according to any one of claims 1-3 and 5, wherein the nucleic acid molecule is condensed with an organic polycation or cationic lipid molecule and the complex formed thereby has a charged copolymer of the general formula I bound to its surface via ionic interaction.

7. (Twice Amended) The combination according to any one of claims 1-3 and 5, containing a therapeutically effective nucleic acid molecule.

B⁴ 8. (Twice Amended) The combination according to any one of claims 1-3 and 5, wherein the carrier consists of a biologically non-resorbable material.

9. (Twice Amended) The combination according to any one of claims 1-3 and 5, wherein the carrier consists of a biologically resorbable material.

B⁵ 12. (Twice Amended) The combination according to any one of claims 1-3 and 5, wherein the carrier is a carrier which is obtainable by cross-linkage of a copolymer as defined in claim 1.

13. (Twice Amended) A method of transferring a nucleic acid molecule into a cell comprising using the combination according to any one of claims 1-3 and 5.

14. (Twice Amended) A pharmaceutical composition comprising the combination according to any one of claims 1-3 and 5.

15. (Added) The combination according to claim 1, wherein I is 1.

REMARKS

Applicants have amended the specification on page 5, lines 12-13 and claim 1 to correct an error that occurred during translation of the international application into English. Specifically, applicants have replaced "have" with "are."